atuveciclib   Click here for help

GtoPdb Ligand ID: 11687

Synonyms: BAY 1143572 | BAY-1143572 | BAY1143572
Compound class: Synthetic organic
Comment: Atuveciclib (BAY 1143572) is an orally active, selective CDK9 inhibitor [2]. It was the first inhibitor of its class to enter clinical development. The potency of atuveciclib is diminished at physiological ATP concentration compared to at the low ATP concentrations used in in vitro assays, Therefore, it was used as the starting point for the development of a more optimised inhibitor enitociclib [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 109.23
Molecular weight 387.12
XLogP 3.02
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COc1cc(F)ccc1c1ncnc(n1)Nc1cccc(c1)C[S@@](=O)(=N)C
Isomeric SMILES COc1c(ccc(c1)F)c1nc(ncn1)Nc1cccc(c1)C[S@](=N)(=O)C
InChI InChI=1S/C18H18FN5O2S/c1-26-16-9-13(19)6-7-15(16)17-21-11-22-18(24-17)23-14-5-3-4-12(8-14)10-27(2,20)25/h3-9,11,20H,10H2,1-2H3,(H,21,22,23,24)/t27-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Atuveciclib has been advanced to clinical evaluation to determine anticancer activity in solid and haematological malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01938638 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1 Interventional Bayer
NCT02345382 Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia Phase 1 Interventional Bayer